DESIGN THERAPEUTICS INC (DSGN) Stock Price & Overview
NASDAQ:DSGN • US25056L1035
Current stock price
The current stock price of DSGN is 10.17 USD. Today DSGN is down by -1.36%. In the past month the price decreased by -1.74%. In the past year, price increased by 141.57%.
DSGN Key Statistics
- Market Cap
- 627.184M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.22
- Dividend Yield
- N/A
DSGN Stock Performance
DSGN Stock Chart
DSGN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DSGN. When comparing the yearly performance of all stocks, DSGN is one of the better performing stocks in the market, outperforming 95.46% of all stocks.
DSGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DSGN. No worries on liquidiy or solvency for DSGN as it has an excellent financial health rating, but there are worries on the profitability.
DSGN Earnings
DSGN Forecast & Estimates
11 analysts have analysed DSGN and the average price target is 13.26 USD. This implies a price increase of 30.38% is expected in the next year compared to the current price of 10.17.
DSGN Groups
Sector & Classification
DSGN Financial Highlights
Over the last trailing twelve months DSGN reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS decreased by -38.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.85% | ||
| ROE | -32.84% | ||
| Debt/Equity | 0 |
DSGN Ownership
DSGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.81 | 362.599B | ||
| AMGN | AMGEN INC | 15.32 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.54 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.28 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.75 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.1 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.42 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DSGN
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Company Info
IPO: 2021-03-26
DESIGN THERAPEUTICS INC
6005 Hidden Valley Road, Suite 110
Carlsbad CALIFORNIA 92011 US
CEO: Joao Siffert
Employees: 54
Phone: 18582934900
DESIGN THERAPEUTICS INC / DSGN FAQ
What does DESIGN THERAPEUTICS INC do?
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Can you provide the latest stock price for DESIGN THERAPEUTICS INC?
The current stock price of DSGN is 10.17 USD. The price decreased by -1.36% in the last trading session.
Does DESIGN THERAPEUTICS INC pay dividends?
DSGN does not pay a dividend.
How is the ChartMill rating for DESIGN THERAPEUTICS INC?
DSGN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting DSGN stock to perform?
11 analysts have analysed DSGN and the average price target is 13.26 USD. This implies a price increase of 30.38% is expected in the next year compared to the current price of 10.17.
What is the employee count for DSGN stock?
DESIGN THERAPEUTICS INC (DSGN) currently has 54 employees.